Contribution of DNA repair mechanisms to determining chemotherapy response in high-grade glioma

Journal of Clinical Neuroscience

Volumn 15, Issue 1, 2008, Pages 1-8

  Parkinson, Jonathon F ^a   Wheeler, Helen T ^a   McDonald, Kerrie L ^a  

^a ROYAL NORTH SHORE HOSPITAL   (Australia)

Author keywords

Antineoplastic agents; Base excision repair; DNA repair; Glioma; MGMT; Mismatch repair; Topoisomerase

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CARMUSTINE; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); ETOPOSIDE; IRINOTECAN; LOMUSTINE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PROCARBAZINE; TEMOZOLOMIDE; THALIDOMIDE; VINCRISTINE;

CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CELL DEATH; CLINICAL TRIAL; COLORECTAL CARCINOMA; DNA REPAIR; DNA REPLICATION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; ESOPHAGUS CARCINOMA; EXCISION REPAIR; GLIOBLASTOMA; HEAD AND NECK CARCINOMA; HUMAN; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; REVIEW; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME; XENOGRAFT;

ANIMALS; DNA REPAIR; DRUG THERAPY; GLIOMA; HUMANS; MODELS, BIOLOGICAL;

EID: 36549066604     PISSN: 09675868     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jocn.2007.06.005     Document Type: Review

References (83)

1. Burnet N.G., Jefferies S.J., Benson R.J., et al. Years of life lost (YLL) from cancer is an important measure of population burden-and should be considered when allocating research funds. Br J Cancer 92 (2005) 241-245
2. Hermanto U., Frija E.K., Lii M.J., et al. Intensity-modulated radiotherapy (IMRT) and conventional three-dimensional conformal radiotherapy for high-grade gliomas: does IMRT increase the integral dose to normal brain?. Int J Radiat Oncol Biol Phys 67 (2007) 1135-1144
3. Walker M.D., Alexander E.J., We H., et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg 49 (1978) 333-343
4. Souhami L., Seiferheld W., Brachman D., et al. Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: report of Radiation Therapy Oncology Group 93-05 protocol. Int J Radiat Oncol Biol Phys 60 (2004) 853-860
5. Stewart L.A. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 359 (2002) 1011-1018
6. Stupp R., Mason W.P., Van Den Bent M.J., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352 (2005) 987-996
7. 6-methylguanine-DNA methyltransferase regulation by p53 in astrocytic cells. Cancer Res 67 (2007) 580-584
8. 6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res 59 (1999) 793-797
9. Hegi M.E., Diserens A.-C., Gorlia T., et al. MGMT silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352 (2005) 997-1003
10. 6-alkylguanine-DNA alkyltransferase: regulation and importance in response to alkylating carcinogenic and therapeutic agents. Cancer Res 50 (1990) 6119-6129
11. 6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma. J Clin Oncol 16 (1998) 3851-3857
12. Esteller M., Garcia-Foncillas J., Andion E., et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 343 (2000) 1350-1354
13. 6-methyl-guanine-DNA methyltransferase methylation in serum and tumor DNA predicts response to 1,3-bis(2-chloroethyl)-1-nitrosourea but not to temozolamide plus cisplatin in glioblastoma multiforme. Clin Cancer Res 9 (2003) 1461-1468
14. 6-methylguanine-DNA methyltransferase, glutathione-S-transferase pi in glioblastoma and the survival of the patients treated with nimustine hydrochloride: an immunohistochemical analysis. Neurol Res 25 (2003) 241-248
15. Yu J., Zhang H., Gu J., et al. Methylation profiles of thirty four promoter-CpG islands and concordant methylation behaviours of sixteen genes that may contribute to carcinogenesis of astrocytoma. BMC Cancer 4 (2004) 65
16. Blanc J.L., Wager M., Guilhot J., et al. Correlation of clinical features and methylation status of MGMT gene promoter in glioblastomas. J Neurooncol 68 (2004) 275-283
17. Paz M.F., Yaya-Tur R., Rojas-Marcos I., et al. CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas. Clin Cancer Res 10 (2004) 4933-4938
18. 6 methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res 10 (2004) 1871-1874
19. 6-methylguanine-deoxyribonucleic acid methyltransferase gene and prognosis in patients with high-grade astrocytic tumors treated with surgery, radiotherapy, and 1-(4-amino-2-methyl-5-pyrimidinyl)methyl-3-(2-chloroethyl)-3-nitrosourea-based chemotherapy. Neurosurgery 54 (2004) 349-357
20. 6-methylguanine-DNA methyltransferase methylation and TP53 mutation in malignant astrocytomas and their relationships with clinical course. Int J Cancer 113 (2005) 581-587
21. 6-methylguanine-DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression in anaplastic gliomas. Clin Cancer Res 11 (2005) 5167-5174
22. Hassler M., Seidl S., Fazeny-Doerner B., et al. Diversity of cytogenetic and pathohistologic profiles in glioblastoma. Cancer Genet Cytogenet 166 (2006) 46-55
23. 6-alkylguanine-DNA alkyltransferase in malignant glioma. Mol Cancer Ther 5 (2006) 2531-2539
24. 6-methylguanine-DNA methyltransferase-deficient phenotype in human gliomas: frequency and time to tumor progression after alkylating agent-based chemotherapy. Clin Cancer Res 5 (1999) 807-814
25. Parkinson J.F., McDonald K.L., Wheeler H., et al. Variation in methylation status of MGMT promoter in serial glioblastoma specimens. Neuro-Oncol 8 (2006) 461-462
26. 6-methylguanine-deoxyribonucleic acid methyltransferase methylation analysis. Neurol Med Chir (Tokyo) 46 (2006) 387-393 discussion 393-4
27. Newlands E.S., Foster T., and Zaknoen S. Phase I study of temozolamide (TMZ) combined with procarbazine (PCB) in patients with gliomas. Br J Cancer 89 (2003) 248-251
28. 6-benzylguanine for patients with recurrent or progressive malignant glioma. J Clin Oncol 23 (2005) 7178-7187
29. Quinn J.A., Pluda J., Dolan M.E., et al. Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma. J Clin Oncol 20 (2002) 2277-2283
30. Koch D., Hundsberger T., Boor S., et al. Local intracerebral administration of O(6)-benzylguanine combined with systemic chemotherapy with temozolomide of a patient suffering from a recurrent glioblastoma. J Neurooncol 82 (2007) 85-89
31. Brock C.S., Newlands E.S., Wedge S.R., et al. Phase I trial of temozolomide using an extended continuous oral schedule. Cancer Res 58 (1998) 4363-4367
32. 6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules. Br J Cancer 88 (2003) 1004-1011
33. Wick W., and Weller M. How lymphotoxic is dose-intensified temozolomide? The glioblastoma experience. J Clin Oncol 23 (2005) 4235-4236
34. Wick W., Steinbach J.P., Schuth J., et al. One week on/one week off regimen of temozolomide for recurrent glioblastoma: A phase III study. J Clin Oncol 22 (2004) 116S
35. Buttolo L., Giunta F., Ferrari V.D., et al. Alternative schedules of adjuvant temozolomide in glioblastoma multiforme: A 6-year experience. J Clin Oncol 24 (2006) 60S
36. 6-methylguanine-DNA methyltransferase gene by glucocortocoid hormone. Oncogene 18 (1999) 525-532
37. 6-methylguanine-DNA methyltransferase by dexamethasone in glioblastomas. J Neurosurg 101 (2004) 659-663
38. Xu G.W., Mymryk J.S., and Cairncross J.G. Inactivation of p53 sensitizes astrocytic glioma cells to BCNU and temozolomide, but not cisplatin. J Neurooncol 74 (2005) 141-149
39. Xu G.W., Mymryk J.S., and Cairncross J.G. Pharmaceutical-mediated inactivation of p53 sensitizes U87MG glioma cells to BCNU and temozolomide. Int J Cancer 116 (2005) 187-192
40. 6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells. J Neurochem 96 (2006) 766-776
41. Martinez R., Schackert H.K., Plaschke J., et al. Molecular mechanisms associated with chromosomal and microsatellite instability in sporadic glioblastoma multiforme. Oncology 66 (2004) 395-403
42. Fink D., Aebi S., and Howell S.B. The role of DNA mismatch repair in drug resistance. Clin Cancer Res 4 (1998) 1-6
43. Fukushima T., Katayama Y., Watanabe T., et al. Promoter hypermethylation of mismatch repair gene hMLH1 predicts the clinical response of malignant astrocytomas to nitrosourea. Clin Cancer Res 11 (2005) 1539-1544
44. Rellecke P., Kuchelmeister K., Schachenmayr W., et al. Mismatch repair protein hMSH2 in primary drug resistance in in vitro human malignant gliomas. J Neurosurg 101 (2004) 653-658
45. Hunter C., Smith R., Cahill D.P., et al. A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy. Cancer Res 66 (2006) 3987-3991
46. Takagi Y., Takahashi M., Sanada M., et al. Roles of MGMT and MLH1 proteins in alkylation-induced apoptosis and mutagenesis. DNA Repair 2 (2003) 1135-1146
47. Liu L.L., Markowitz S., and Gerson S.L. Mismatch repair mutations override alkyltransferase in conferring resistance to temozolomide but not to 1,3-bis(2-chloroethyl)nitrosourea. Cancer Res 56 (1996) 5375-5379
48. Tentori L., and Graziani G. Pharmacological strategies to increase the antitumor activity of methylating agents. Curr Med Chem 9 (2002) 1285-1301
49. Friedman H.S., Kerby T., and Calvert H. Temozolomide and treatment of malignant glioma. Clin Cancer Res 6 (2000) 2585-2597
50. Ratnam K., and Low J.A. Current development of clinical inhibitors of poly (ADP-ribose) polymerase in oncology. Clin Cancer Res 13 (2007) 1383-1388
51. Cheng C.L., Johnson S.P., Keir S.T., et al. Poly(ADP-ribose) polymerase-1 inhibition reverses temozolomide resistance in a DNA mismatch repair-deficient malignant glioma xenograft. Mol Cancer Ther 4 (2005) 1364-1368
52. Tentori L., Portarena I., Torino F., et al. Poly(ADP-ribose) polymerase inhibitor increases growth inhibition and reduces G(2)/M cell accumulation induced by temozolomide in malignant glioma cells. Glia 40 (2002) 44-54
53. Khan O.A., and Pilch D.S. Topoisomerase I-mediated DNA cleavage induced by the minor groove-directed binding of bibenzimidazoles to a distal site. J Mol Biol 365 (2007) 561-569
54. Jensen P.B., and Sehested M. DNA topoisomerase II rescue by catalytic inhibitors: a new strategy to improve the antitumor selectivity of etoposide. Biochem Pharmacol 54 (1997) 755-759
55. Franceschi E., Cavallo G., Scopece L., et al. Phase II trial of carboplatin and etoposide for patients with recurrent high-grade glioma. Br J Cancer 91 (2004) 1038-1044
56. Coggins C.A., Elion G.B., Houghton P.J., et al. Enhancement of irinotecan (CPT-11) activity against central nervous system tumor xenografts by alkylating agents. Cancer Chemother Pharmacol 41 (1998) 485-490
57. Friedman H.S., Petros W.P., Friedman A.H., et al. Irinotecan therapy in adults with recurrent or progressive malignant glioma. J Clin Oncol 17 (1999) 1516-1525
58. Batchelor T.T., Gilbert M.R., Supko J.G., et al. Phase 2 study of weekly irinotecan in adults with recurrent malignant glioma: Final report of NABTT 97-11. Neuro-oncol 6 (2004) 21-27
59. Prados M.D., Lamborn K., Yung W.K.A., et al. A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: A North American Brain Tumor Consortium study. Neuro-oncol 8 (2006) 189-193
60. Reardon D.A., Quinn J.A., Rich J.N., et al. Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma. Cancer 104 (2005) 1478-1486
61. Stark-Vance V. Bevacizumab and CPT-11 in the treatment of relapsed malignant glioma. Neuro-oncol 7 (2005) 369
62. Ho D.M., Hsu C.Y., Ting L.T., et al. MIB-1 and DNA topoisomerase II alpha could be helpful for predicting long-term survival of patients with glioblastoma. Am J Clin Pathol 119 (2003) 715-722
63. Holden J.A., and Townsend J.J. DNA topoisomerase II-alpha as a proliferation marker in astrocytic neoplasms of the central nervous system: correlation with MIB1 expression and patient survival. Mod Pathol 12 (1999) 1094-1100
64. Miettinen H.E., Jarvinen T.A., Kellner U., et al. High topoisomerase IIalpha expression associates with high proliferation rate and and poor prognosis in oligodendrogliomas. Neuropathol Appl Neurobiol 26 (2000) 504-512
65. Park S.H., and Suh Y.L. Expression of cyclin A and topoisomerase IIalpha of oligodendrogliomas is correlated with tumour grade, MIB-1 labelling index and survival. Histopathology 42 (2003) 395-402
66. Bredel M., Piribauer M., Marosi C., et al. High expression of DNA topoisomerase IIalpha and Ki-67 antigen is associated with prolonged survival in glioblastoma patients. Eur J Cancer 38 (2002) 1343-1347
67. Faria M.H.G., Goncalves B.P.A., do Patrocinio R., et al. Expression of Ki-67, Topoisomerase II alpha and c-MYC in astrocytic tumors: Correlation with the histopathological grade and proliferative status. Neuropathology 26 (2006) 519-527
68. Stein M.E., Kuten A., Drumea K., et al. Carboplatin and etoposide for recurrent malignant glioma following surgical and radiotherapy failure: A clinical study conducted at the Northern Israel Oncology Center. J Surg Oncol 71 (1999) 167-170
69. Watanabe K., Kanaya H., Fujiyama Y., et al. Combination chemotherapy using carboplatin (JM-8) and etoposide (JET therapy) for recurrent malignant gliomas: a phase II study. Acta Neurochir (Wien) 144 (2002) 1265-1270
70. Korones D.N., Smith A., Foreman N., et al. Temozolomide and oral VP-16 for children and young adults with recurrent or treatment-induced malignant gliomas. Pediatr Blood Cancer 47 (2006) 37-41
71. Korones D.N., Benita-Weiss M., Coyle T.E., et al. Phase I study of temozolomide and escalating doses of oral etoposide for adults with recurrent malignant glioma. Cancer 97 (2003) 1963-1968
72. Cairncross J.G., Ueki K., Zlatescu M.C., et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 90 (1998) 1473-1479
73. Morokoff A.P., and Novak U. Targeted therapy for malignant gliomas. J Clin Neurosci 11 (2004) 807-818
74. Wong M.L., Kaye A.H., and Hovens C.M. Targeting malignant glioma survival signalling to improve clinical outcomes. J Clin Neurosci 14 (2007) 301-308
75. Soni D., King J.A., Kaye A.H., et al. Genetics of glioblastoma multiforme: mitogenic signaling and cell cycle pathways converge. J Clin Neurosci 12 (2005) 1-5
76. Mellinghoff I.K., Wang M.Y., Vivanco I., et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 353 (2005) 2012-2024
77. Warusavitarne J., and Schnitzler M. The role of chemotherapy in microsatellite unstable (MSI-H) colorectal cancer. Int J Colorectal Dis 22 (2007) 739-748
78. 6-methylguanine-DNA methyltransferase by promoter hypermethylation and its relationship to aflatoxin B1-DNA adducts and p53 mutation in hepatocellular carcinoma. Int J Cancer 103 (2003) 440-444
79. 6-methylguanine-DNA methyltransferase gene: epigenetic silencing and prognostic value in head and neck squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev 13 (2004) 967-975
80. 6-methylguanine-DNA methyltransferase (MGMT) promotor hypermethylation in esophageal adenocarcinoma. Int J Cancer 119 (2006) 264-268
81. 6-methylguanine-DNA methyltransferase and p53 mutation in diffuse large B-cell lymphoma. Int J Hematol 84 (2006) 248-255
82. Esteller M., Risques R.A., Toyota M., et al. Promoter hypermethylation of the DNA repair gene O(6)-methylguanine-DNA methyltransferase is associated with the presence of G:C to A:T transition mutations in p53 in human colorectal tumorigenesis. Cancer Res 61 (2001) 4689-4692
83. Wolf P., Hu Y.C., Doffek K., et al. O(6)-methylguanine-DNA methyltransferase promoter hypermethylation shifts the p53 mutational spectrum in non-small cell lung cancer. Cancer Res 61 (2001) 8113-8117